Tools / Drugs Amantadine hydrochloride Treats dyskinesia. Sold as Symmetrel, Gocovri, Osmolex ER. Every FDA application for this active ingredient: 6 branded and 37 generic.
As of Nov 21, 2026, FDA lists 43 applications for Amantadine hydrochloride (sold as Symmetrel, Gocovri, Osmolex ER), first approved Feb 14, 1968, with 4 new uses approved and 0 published complete response letters.
Applications : 43 New uses approved : 4 Complete response letters : 0 Medicare spending, 2025 : $146M Mechanism of action and target, from ChEMBL Uses, approved and in trials Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Postencephalitic Parkinson disease Approved
Secondary Parkinson disease Approved
Intracranial arteriosclerosis Approved
Parkinsonian disorders Approved NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Feb 14, 1968 Symmetrel NDA 16023 · New dosage form Endo Pharmaceuticals20 Discontinued Jul 20, 1976 Symmetrel NDA 17118 · New indication Endo Pharmaceuticals9 Discontinued Nov 3, 1980 Symmetrel NDA 18101 · New dosage form Endo Pharmaceuticals9 Discontinued Jan 7, 1987 Amantadine Hydrochloride ANDA 70589 Upsher-Smith Laboratories29 Marketed Feb 18, 1987 Amantadine Hydrochloride ANDA 71293 Sandoz26 Marketed Oct 30, 1990 Amantadine Hydrochloride ANDA 72655 G & W Laboratories10 Discontinued Aug 23, 1991 Amantadine Hydrochloride ANDA 73115 Teva Pharmaceuticals7 Discontinued Jun 28, 1993 Amantadine Hydrochloride ANDA 74028 Chartwell RX12 Marketed Oct 28, 1994 Amantadine Hydrochloride ANDA 74170 Aurobindo Pharma USA4 Marketed Jul 17, 1995 Amantadine Hydrochloride ANDA 74509 Pharmaceutical Associates12 Marketed Dec 24, 1998 Amantadine Hydrochloride ANDA 75060 PharmoBedient6 Marketed Sep 11, 2002 Amantadine Hydrochloride ANDA 75819 PharmoBedient3 Discontinued Dec 16, 2002 Amantadine Hydrochloride ANDA 76186 Upsher-Smith Laboratories6 Marketed Sep 10, 2004 Amantadine Hydrochloride ANDA 76352 Chartwell RX2 Discontinued Feb 23, 2006 Amantadine Hydrochloride ANDA 77659 Actavis Elizabeth2 Discontinued Dec 12, 2006 Amantadine Hydrochloride ANDA 77992 PH Health4 Discontinued May 29, 2008 Amantadine Hydrochloride ANDA 78720 Bionpharma4 Marketed May 31, 2016 Amantadine Hydrochloride ANDA 208278 Zydus Pharmaceuticals (USA)2 Marketed Sep 30, 2016 Amantadine Hydrochloride ANDA 207570 InvaGen Pharmaceuticals1 Discontinued Dec 6, 2016 Amantadine Hydrochloride ANDA 208107 Watson Laboratories2 Discontinued Dec 15, 2016 Amantadine Hydrochloride ANDA 208096 Watson Laboratories1 Discontinued Jan 31, 2017 Amantadine Hydrochloride ANDA 207571 InvaGen Pharmaceuticals1 Discontinued Jun 7, 2017 Amantadine Hydrochloride ANDA 209047 Strides Pharma1 Marketed Jun 9, 2017 Amantadine Hydrochloride ANDA 209035 Strides Pharma1 Marketed Jun 12, 2017 Amantadine Hydrochloride ANDA 209171 Heritage Pharmaceuticals1 Marketed Jun 15, 2017 Amantadine Hydrochloride ANDA 209221 Chartwell Molecular1 Discontinued Jun 21, 2017 Amantadine Hydrochloride ANDA 208966 Alembic1 Marketed Aug 24, 2017 Gocovri NDA 208944 · New dosage form Supernus Pharmaceuticals3 Marketed Feb 7, 2018 Amantadine Hydrochloride ANDA 210403 Jubilant Generics2 Discontinued Feb 16, 2018 Osmolex ER NDA 209410 · New dosage form Supernus Pharmaceuticals1 Discontinued Mar 2, 2020 Amantadine Hydrochloride ANDA 210129 Rising Pharmaceuticals1 Marketed Mar 10, 2020 Amantadine Hydrochloride ANDA 210215 PharmoBedient1 Marketed May 21, 2020 Amantadine Hydrochloride ANDA 212044 Rubicon Research1 Marketed Oct 15, 2020 Amantadine Hydrochloride ANDA 214284 Alembic1 Marketed Aug 20, 2021 Amantadine Hydrochloride ANDA 214178 PharmoBedient1 Marketed Feb 18, 2022 Amantadine Hydrochloride ANDA 211354 ONESOURCE1 Marketed May 27, 2022 Amantadine Hydrochloride ANDA 212407 Adaptis1 Discontinued Dec 20, 2022 Amantadine Hydrochloride ANDA 214580 Humanwell Puracap1 Marketed Aug 26, 2024 Amantadine Hydrochloride, Amantadine ANDA 214897 Zydus1 Discontinued Sep 26, 2024 Amantadine Hydrochloride ANDA 218598 Zhejiang Jutai Pharmaceutical1 Marketed — Symmetrel NDA 16020 Endo Pharmaceuticals0 Discontinued — Symadine ANDA 71000 Solvay0 Discontinued — Amantadine Hydrochloride ANDA 71382 Watson Laboratories0 Discontinued
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Gocovri Part D $124M +24% 5,677 Amantadine Part D $22.6M −3% 109,422 Osmolex ER Part D $0 −100% 0
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Amantadine $5.4M for 225,825 prescriptions, +1% on 2024
Gocovri $5.0M for 1,537 prescriptions, +11% on 2024 Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change Amantadine 100 mg capsule: $0.141 per unit Generic · −5% in a year Amantadine 100 mg tablet: $0.310 per unit Generic · −21% in a year Amantadine 50 mg/5 mL solution: $0.050 per mL Generic · +3% in a year How its trials ended 39 ClinicalTrials.gov studies testing it, classified by TrialPanorama , partly automatically, so some labels are wrong Of the 10 whose ending is known, 10% met their primary endpoint, 20% missed it and 70% stopped early.
Completed, result not reported 13 33%Completed, result not reported Count13 Share33% Status unknown 9 23%Status unknown Count9 Share23% Ongoing 7 18%Ongoing Count7 Share18% Stopped: other or unclear 5 13%Stopped: other or unclear Count5 Share13% Missed its primary endpoint 2 5%Missed its primary endpoint Count2 Share5% Met its primary endpoint 1 3%Met its primary endpoint Count1 Share3% Stopped: lack of efficacy 1 3%Stopped: lack of efficacy Count1 Share3% Stopped: sponsor or business decision 1 3%Stopped: sponsor or business decision Count1 Share3% Trials that missed or stopped early NCT04952519 Stopped early: “The annual analysis did not show the efficacy of the investigational medicinal product in this application, therefore the study was not continued.” Adverse event reports (FAERS) Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files . A report does not show the drug caused the event.
Cases 192
Serious 106 (55%)
Deaths reported 21
By quarter 2025 Q4: 55 · 2026 Q1: 40 · 2026 Q2: 40 · 2026 Q3: 57
Most reported reactions Hallucination (24), Mental status changes (21), Off label use (20), Fall (18), Tremor (14), Product use issue (13), Dry mouth (12), Constipation (11), Drug ineffective (11), Fatigue (10) 39 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Breast Cancer, Peripheral Neuropathy Due to Chemotherapy · Al-Azhar University Phase 2 Not yet recruiting Oct 22, 2026 Memantine Targeting Neurovascular Dysfunction After Mild and Moderate Traumatic Brain Injury (MEND) Traumatic Brain Injury, Mild Traumatic Brain Injury · Nova Scotia Health Authority Phase 2 Not yet recruiting Oct 9, 2026 Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression Major Depression · Mclean Hospital Early phase 1 Recruiting May 1, 2026 Escalating Doses of Memantine in Down Syndrome (MEDS-123) Down Syndrome, Intellectual Disability · University Hospitals Cleveland Medical Center Phase 1 Not yet recruiting Apr 15, 2026 Neuroprotection of Memantine and Rosuvastatin Peripheral Nerve Disease · Tanta University Phase 2 / Phase 3 Not yet recruiting Mar 31, 2026 Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain Brain Tumor · The University of Texas Health Science Center at San Antonio Phase 2 Recruiting Mar 13, 2026 Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome Amantadine, Duloxetine · Cairo University Not applicable Recruiting Feb 19, 2026 Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia Alzheimer Type Dementia · Bigespas LTD Phase 3 Recruiting Nov 26, 2025
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA